Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxygen therapy device risks warrant continued prescription labeling -- FDA petition response.

This article was originally published in The Gray Sheet

Executive Summary

OXYGEN THERAPY EQUIPMENT RECALLS, ADVERSE EVENTS WARRANT Rx LABELING, FDA says in a Sept. 15 denial of petitions filed in 1991 by the California Association of Medical Product Suppliers (CAMPS) and the New England Medical Equipment Dealers. One reason that the equipment should not be exempt from prescription requirements, FDA says, is that agency records show that oxygen therapy devices have been associated with "eight recalls (five Class II and three Class III) and two Safety Alerts." In addition, FDA found 58 adverse event reports consisting of "8 deaths, 10 serious injuries and 40 malfunctions."
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004830

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel